SCHEMBL2467763

SCHEMBL2467763

Nc1ccc2[nH]nc(Br)c2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 6/20 0.53
PDPK1 O15530 4/20 0.53
GSK3B P49841 1/20 0.51
AXL P30530 2/20 0.46
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR2B P41595 1/20 0.45
AURKA O14965 1/20 0.42
KDM4E B2RXH2 3/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
ROCK2 O75116 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
RAB9A P51151 1/20 0.41
ROCK1 Q13464 1/20 0.41
HIF1A Q16665 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29644080 1.00 JAK2 (0.53) JAK2PDPK1GSK3BAXLHTR2A
SCHEMBL7571940 0.84 PDPK1 (0.53) JAK2PDPK1GSK3BAXLAURKA
SCHEMBL30860966 0.84 PDPK1 (0.53) JAK2PDPK1GSK3BAXLAURKA
SCHEMBL118573 0.81 JAK2 (0.64) JAK2PDPK1GSK3BAXLHTR2A
SCHEMBL30855645 0.79 PDPK1 (0.68) JAK2PDPK1GSK3BAXLHTR2A
SCHEMBL31584704 0.76 MAP2K4 (0.53) JAK2PDPK1KDM4EMAPTALDH1A1
SCHEMBL7571499 0.76 GSK3B (0.51) JAK2PDPK1GSK3BAXLHTR2A
SCHEMBL4004201 0.76 GSK3B (0.51) JAK2PDPK1GSK3BAXLHTR2A
SCHEMBL266855 0.76 GSK3B (0.56) JAK2PDPK1GSK3BAXLHTR2A
SCHEMBL759158 0.76 GSK3B (0.51) JAK2PDPK1GSK3BAXLHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116332950-A Indazole substituted podophyllotoxin derivative and preparation method and application thereof 汤亚杰 2023-06-27 CN claimed
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS RAPPORT THERAPEUTICS, INC. 2025-07-17 US disclosed
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators RAPPORT THERAPEUTICS, INC. (US) 2025-05-20 US disclosed
CN-118976029-A Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis 韩国化学研究院 2024-11-19 CN disclosed
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-19 US disclosed
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2024-11-12 US disclosed
US-20240270698-A2 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-08-15 US disclosed
CN-114829344-B Pyrimidine derivatives and pharmaceutical compositions containing the same 韩国化学研究院 2024-08-13 CN disclosed
US-20230348399-A1 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-11-02 US disclosed
US-20230348399-A1 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2023-11-02 US disclosed
WO-2005082890-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-09 WO disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 US disclosed
US-20050054662-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2005-03-10 US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 US disclosed
EP-1444211-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2004-08-11 EP disclosed
US-20040138286-A1 Rho kinase inhibitors DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2004-07-15 US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 US disclosed
EP-1403255-A1 Rho KINASE INHIBITORS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2004-03-31 EP disclosed
WO-2003040109-A2 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 JAK2 262/4885PDPK1 61/4885GSK3B 75/4885
US-20050054662-A1 Quinazoline derivatives as antitumor agents ERBB2, ERBB3, ABL1 JAK2 7/4885PDPK1 262/4885GSK3B 573/4885
US-12139485-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A JAK2 809/4885PDPK1 3115/4885GSK3B 2690/4885
US-12145934-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A JAK2 809/4885PDPK1 3115/4885GSK3B 2690/4885
US-20240270698-A2 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF LRRK2, PFKL, PDK3 JAK2 982/4885PDPK1 15/4885GSK3B 333/4885
US-20040138286-A1 Rho kinase inhibitors ROCK1, ROCK2, ARHGDIA JAK2 929/4885PDPK1 425/4885GSK3B 577/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 JAK2 272/4885PDPK1 94/4885GSK3B 100/4885
US-12304908-B2 Azabenzimidazoles and their use as AMPA receptor modulators GRIN1, GRIN2B, GRIN3A JAK2 809/4885PDPK1 3115/4885GSK3B 2690/4885
US-20250230157-A1 AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN1, GRIN2B, GRIN3A JAK2 807/4885PDPK1 3052/4885GSK3B 2720/4885
US-20230348399-A1 NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF LRRK2, PFKL, PDK3 JAK2 982/4885PDPK1 15/4885GSK3B 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.